SSRIs antidepressant activity is influenced by Gβ3 variants

Alessandro Serretti, Cristina Lorenzi, Cristina Cusin, Raffaella Zanardi, Enrico Lattuada, David Rossini, Roberta Lilli, Adele Pirovano, Marco Catalano, Enrico Smeraldi

Research output: Contribution to journalArticlepeer-review


The aim of the present study was to test a possible effect of the G-protein β3-subunit (Gβ3) C825T gene variant on the antidepressant activity of selective serotonin reuptake inhibitors (SSRIs) in a sample of major and bipolar depressives, with or without psychotic features. Four hundred and ninety inpatients were treated with fluvoxamine 300 mg/day (n=362) or paroxetine 40 mg/day (n=128) and either placebo or pindolol in a double-blind design for 6 weeks. The severity of depressive symptoms was weekly assessed with the Hamilton Rating Scale for Depression. Gβ3 allelic variants were determined in each subject using a PCR-based technique. Subjects with Gβ3 T/T variants showed better response to treatment (P=0.009) and this effect was independent from analyzed demographic and clinical variables. These results confirm preliminary reports and shed further light on the genetics of the response to antidepressant treatments.

Original languageEnglish
Pages (from-to)117-122
Number of pages6
JournalEuropean Neuropsychopharmacology
Issue number2
Publication statusPublished - Mar 2003


  • Antidepressant treatment
  • Fluvoxamine
  • Mood disorders
  • Paroxetine
  • Pharmacogenetics

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)


Dive into the research topics of 'SSRIs antidepressant activity is influenced by Gβ3 variants'. Together they form a unique fingerprint.

Cite this